IMNN
Imunon Inc (IMNN)
Healthcare • NASDAQ • $1.64+3.80%
- Symbol
- IMNN
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.64
- Daily Change
- +3.80%
- Market Cap
- $9.26M
- Trailing P/E
- N/A
- Forward P/E
- -0.93
- 52W High
- $6.96
- 52W Low
- $1.47
- Analyst Target
- $17.00
- Dividend Yield
- N/A
- Beta
- 1.97
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was…
Company websiteResearch IMNN on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.